The Multicentre Selective Lymphadenectomy Trial - 3

The goal of this clinical trial is to demonstrate that there is no difference (non-inferiorty) in the 2 year recurrence-free survival (RFS) between 2 different surgical approaches for clinical Stage III melanoma. Following 6 weeks of standard neaodjuvant immunotherapy, patients will undergo either selective index lymph node resection (ILN) (identified at baseline as the largest affected lymph node) or the standard of care therapeutic lymph node dissection (TLND). The secondary aims are to assess if patients who are managed without TLND will have a reduction in surgical complications (less wound problems \& lymphoedema), an improved quality of life, at a lower healthcare utilisation.

NCT Number	NCT07049276
Lead Sponsor	Melanoma Institute Australia
Conditions	Cutaneous Melanoma, Stage III
Enrollment	1,500 participants
Start Date	2025-10-01
Primary Completion	2030-08 (estimated)
Study Completion	2040-08 (estimated)
Updated on ClinicalTrials.gov	2026-06-29